Trevi Therapeutics (TRVI) Income towards Parent Company (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Income towards Parent Company of -$13.2 million for Q1 2026, down 27.58% year-over-year from -$18.2 million in Q1 2025, and down 58.73% quarter-over-quarter from -$8.3 million in Q4 2025.
Trevi Therapeutics (TRVI) Income towards Parent Company (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$13.2 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 27.58% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$45.6 million (up 3.58% YoY), while the FY2025 annual figure was -$42.8 million, up 10.67% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$13.2 million, down from -$8.3 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$5.5 million in Q4 2022, with the low at -$13.2 million in Q3 2024.
- The 5-year median for Income towards Parent Company is -$8.3 million (2025), against an average of -$9.5 million.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company surged 35.39% in 2022, then slumped 72.88% in 2024.
- Trevi Therapeutics' Income towards Parent Company stood at -$5.5 million in 2022, then tumbled by 42.07% to -$7.8 million in 2023, then sank by 45.29% to -$11.4 million in 2024, then grew by 26.86% to -$8.3 million in 2025, then tumbled by 58.73% to -$13.2 million in 2026.
- Business Quant data shows TRVI's Income towards Parent Company at -$13.2 million in Q1 2026, -$8.3 million in Q4 2025, and -$11.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -17.80 Mn |
| Mar 31, 2026 | -13.19 Mn |
| Dec 31, 2025 | -8.31 Mn |
| Sep 30, 2025 | -11.80 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -10.34 Mn |
| Dec 31, 2024 | -11.36 Mn |
| Sep 30, 2024 | -13.24 Mn |
| Jun 30, 2024 | -12.35 Mn |
| Mar 31, 2024 | -10.90 Mn |
| Dec 31, 2023 | -7.82 Mn |
| Sep 30, 2023 | -7.70 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -6.40 Mn |
| Dec 31, 2022 | -5.51 Mn |
| Sep 30, 2022 | -8.27 Mn |
| Jun 30, 2022 | -8.05 Mn |
| Mar 31, 2022 | -7.33 Mn |
| Dec 31, 2021 | -8.52 Mn |
| Sep 30, 2021 | -7.26 Mn |